Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for Prostate Cancer
Phase 2
95
about 3.7 years
18+
Male only
1 site in CA
What this study is about
This trial is testing a treatment with apalutamide, a hormone therapy, combined with image-guided stereotactic body radiation therapy (SBRT) for prostate cancer. The goal of this treatment is to stop the growth of prostate tumor cells that need testosterone to grow.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Gallium Ga 68 Gozetotide
- 2.Questionnaire Administration
- 3.Receive Guided Stereotactic Body Radiation Therapy
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
apalutamide, gallium (68Ga) gozetotide
oral (Oral Tablet)
Secondary: Longitudinal PROs on the EPIC-26 questionnaire in the sexual, urinary, and bowel domains, PROs on the EPIC-26 bowel domain, Patient-reported outcomes (PROs) on the Expanded Prostate Cancer Index Composite-26 (EPIC-26) urinary domain, Radiographic persistence of disease on multiparametric magnetic resonance imaging, Radiographic persistence of disease on prostate specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)
diagnostic, imaging, radiation
Oncology